Member Info for Kong1

So clinical study approved which is great news but due to Covid, it’s looking like we arnt going to see any results from the first phase until Oct / November
So in the mean time, I look forward to
Results of the BAMS testing
C.E. Approved markings
Would like to see orders from the UK government and orders from Europe
And a upbeat trading statement
And positive news flow from all the other companies that Avacta has been partnering up with over recent months
And going forward any other partnerships where affirmers can and will play a huge part in

2 wells producing on average 1100 BOPD each, now with this new well we should be looking at over 3000 BOPD
And as the CEO mentions, the 3rd well will be in production very quickly.
The drilling guys will be moving on to the next well very shortly so aprox 2 months from now, fingers crossed we should see production of oil from this 3rd well just now along with hopefully good news of another find and again aprox 2 months after that production will commence doubling our BOPD as if our figures now..
Lots of upside in this company with good returns and low cost production rates and regularly monthly payments from the Egyptian Government
Hopefully Covid will start to subside and businesses starting to get back to normality which in turn should require more oil and higher prices
Can’t see no reason why 10p can not be achieved by the end of year or sooner

The very large buy has swallowed up all the sells today, A crossed transaction between the market makers at 3.89should give us a very good chance of breaking the 4p barrier.

Again and thanks Bebeto, the new well coming on stream shortly hopefully will give us close to 3,000 BOPD creating circa $40m, not sure what profits will be, but being a low cost company, could give them a healthy return and then you realise of the price target of 26p that has been given.
certainly 10p seems more than achievably. a very healthy return for investers, hopefully more investers are starting to take note, the number of trades are starting to rise of late for sure

I get alot more but i might be having a blonde moment but always willing to accept if i`m wrong

so here goes, and this is without any new BOPD from the new well.
2,200 BOPD as stated in last trading statement. $40.00 per barrel = $88,000 a day x 365 days a year = $32,120.00 a year

then you have thave potential of the new well weve just found and the potential of another one in aprox 7 weeks time ?

I will stand corrected if i`ve dropped a *******

I wonder if that last trade was a buy or a sell ? interesting all the same

well after yesterday which blew me away with the lack of trades and sp, i`m a little relieved at many more positive trades today.
Also a thank you to Bebeto for the link to the interview today,
I thought a good interview, knew his answers and seemed very positive as to where theve come from in a very short space of time.
Totally Blown away with the time scale of spudding to testing to production, Staggered to be honest.
in aprox 4 weeks time we will see oil be pumped out of the ground and payments every 4 weeks, astonshing.

Another promising drill to be started in the next 2 or 3 weeks after testing on this well and as suggested in the interview if all goes well aprox 4 weeks after test hole drilled another well could be producing.

26p target has been anounced so I cant see no reason why in the next 12 months at least 10p cant be achieved.

good luck to all and what appears a much better trading day

Kong

I’ve blocked quick draw but I know he went on a rant earlier this week about no news,
Can someone let him know Alastair has delivered what he’s promised

Having seen the RNS this morning, I was sure this was going to hit 4p, everything paid for, a new well that is going to come on stream quite quickly, revenue coming into their bank.
i`m totally shocked by the lack of trades or number of trades should i say. UOG have just acquired another oil field that will be producing oil and revenue very very shortly.

I`m speechless

Professor Sharon pea**** in a speech to the BBC has said that the new covid 19 variant Kent version is going to sweep the world and be the most dominant and she expects for this variant being around for another 10 years !!!!
If that’s the case then Avacta are going to be busy for some time and money made will pay all costs bringing the cancer trials and any other new programmes to the fore

Hi optimus

I think this share may drop a bit more yet, but when the corridors open again this will quickly rise.

im not invested here at the moment, just keeping it on my radar, im heavily into AVACTA hoping we get good results in our test which then in turn, will open up the holiday markets, and air lines.
this directors award this morning really got me angry when you realise what a mess the industry is in and they award themselves this.

it stinks

Volcano

are you seriously reading the thread me and optimus have posted because your reply has got nothing in the slightest to do with director awards.
your post and view is totally irrelevant to our posts

Hi optimus
Yes a disgrace this is. The nomads should be ashamed for allowing this to happen.
I can’t say what the share price will do as I don’t have a crystal ball, but my feeling is that it will drop some more before it hits bottom.
The only thing that will stop the rot and stabilise the share price is when there is news of easing of flights and holiday then I think it will come back up.
But at the moment this news is disgraceful

So the company is on its knees and the directors award themselves 700 thousand shares
It’s a disgrace, the nomads want to be ashamed of themselves for allowing this to happen.
Yes they may have met certain criteria’s to be given these shares but that was when the company was doing ok
Circumstances have changed and if the government has helped financially this company to stay afloat then I am disgusted in this RNS and makes a mockery of the situation the company is in
A ——— disgrace

Having had a look at this latest RNS with Mologic and the previous RNS. I am seeing a pattern emerging on how great the tests are in lab results.
AS is constantly driving how good Affimers are in Laboratory conditions and we are now waiting on clinical evaluation, to give us the proof we need and the C.E markings.
I suspect once we have this, our test should be rated as the finest test in the world and every country will want us, However, I suspect it will come down to how many Avacta can supply, but AS has already said he is speaking to other manufacturing companies, you just wouldn`t if you have any doubt the product wouldn`t work.

Avacta is also starting to team up with a number of organisations, that are wanting to evaluate Affimers and its technologys.
This side is starting to make me think, in that if you have a product that is far superior and cheaper to create than any other product on the market in the world, why as a health organisation would you want another product that may be potentially higher in cost but has a poorer ability over Avacta and Affimers.
so as a CEO of another company would you spend millions of £s developing a test, whatever it may be for Avacta to come along and make one better and cheaper ?
Avacta over the next 2 years or so may be able to make numerous tests that just make all other companies tests redundant.
They literally may change the way things are now conducted.

The same could also happen to the way cancer is treated, it will take several years of clinical testing but if Avacta can prove that the Affimmers work the same way which they have found in the labs, Avacta literally could become one or the biggest medical company in the world.

The company is not a one stop covid shop that Alistar has previously mentioned but it is certainly highlighting Avacta and Affimmers on a Global scale with its abilities, once CE markings has been granted it will have rubber stamped Avacta and put them on the Global map !

Kong

I’ve got to say I’m now becoming astounded by the length of time this is taking, considering we are in a pandemic. Considering the government is panicking in trying to do everything it can, even buying inferior Chinese products, that gave the world this bloody disease.
I really really can’t understand why in 6 weeks of clinical validation we still haven’t herd anything. I don’t believe it takes so long to find out if it works in a public environment with the general public using the products. Surely you would know after a day or two if it’s a simple test like they say it is and anyone can use it.
The only consolation that is keeping my hopes up that it works, is if it didn’t surely they would have told us by now.
But it’s a tough one

So we are into our 6th week of validation and I’m struggling to understand how or why it is taking so long for the clinical trial to be completed.

Ab8dct
In a nutshell that’s about where my thoughts are with this,
It’s took to long to get to this collaboration and it’s not world besting news, but it is positive news and I see this as news that the Lft is still on target otherwise this wouldn’t have happened.
It gives me hope all these tests work as it gives me more hope that the cancer tests will work as well.
This is now 5 weeks since AS mentioned we are in clinical trials, how long does it take to confirm it works

I might not have coppied it all but hes the link

https://www.sharebuyers.co.uk/shares/avacta-shares-going-for-growth-world-moving-rapidly-again/

Ive just stumbled upon this and yes I know we are aware of some or all of it but I thought it was a good read and highlighted a few of the things AVACTA are trying to achieve.

As part of the ShareBuyers’ going for growth series, we take a look into the growth prospects of Avacta (LON: AVCT), a specialist developer of innovative cancer therapies and diagnostics tools that has been among the best performers across the London markets this year with a gain of over 800% since the start the year.

With its diagnostics division preparing to launch a game-changing saliva-based COVID-19 rapid antigen test that can easily be used at home and read by eye – its surging share price comes as little surprise due to the immense potential to easily support frequent mass testing with the minimal of fuss and unlock the wider economy.

In the UK alone, the demand for antigen testing in the community could be as high as 100 million tests per month in the medium-term. Through our partnerships, we are looking to supply beyond just the UK market.

Alastair Smith, CEO of Avacta
Find out why Avacta Chief Executive Officer Alastair Smith feels that the business is on its way to becoming a multi-billion dollar life sciences company that can compete on the world stage with the likes of Roche-Genentech and find out how he’d pitch the business to legendary investor Warren Buffett!

Firstly, can you please tell us a bit about Avacta and its value proposition?
Avacta is developing novel cancer immunotherapies and powerful diagnostic tests, using its two proprietary platforms – Affimer® binding proteins and pre|CISIONTM tumour-targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients and to deliver powerful diagnostic tests for a range of conditions.

Affimer binding proteins can be generated quickly to bind to drug targets in order to develop novel therapeutic agents, and to biomarkers of disease allowing a range of diagnostic tests to be developed. Affimer proteins have technical and commercial benefits over antibodies but essentially they can be thought of as simple, robust, powerful and low cost alternatives to antibodies that can be applied in therapeutic and diagnostic markets worth in excess of $150bn.

Avacta’s proprietary pre|CISION targeted chemotherapy platform releases the active drug only in the tumour, thereby reducing systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta is developing these targeted chemotherapies with the longer-term goal of linking them with Affimer immunotherapies as combined treatments and drug conjugates. In simple terms, pre|CISION drugs aim to provide patients with chemotherapy without the side effects.

Avacta is in a position to help shape the future of medicine through powerful new anti-cancer treatments and diagnostics. With appropriate scale-up cap

Very interesting and surprised to see this,
Not been on here for months, not sure why I looked today but I did.

Good luck all